|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3435363738394041424344...6768» |
- Empliciti (elotuzumab) / AbbVie, BMS
Biomarker, Trial primary completion date, Monotherapy: Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma (clinicaltrials.gov) - May 20, 2014
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2014 --> Apr 2014
- | Empliciti (elotuzumab) / AbbVie, BMS
Biomarker, Trial initiation date, Monotherapy: Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma (clinicaltrials.gov) - May 20, 2014
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2014 --> Apr 2014 Initiation date: Feb 2012 --> Dec 2011
- | Empliciti (elotuzumab) / AbbVie, BMS
Biomarker, Enrollment open, Monotherapy: Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma (clinicaltrials.gov) - May 20, 2014
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Feb 2012 --> Dec 2011 Active, not recruiting --> Recruiting
- | Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial primary completion date, Surgery: WONDERS: Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (clinicaltrials.gov) - May 18, 2014
P3, N=30, Completed, Sponsor: Octapharma
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Feb 2014
- Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial completion date, Surgery: WONDERS: Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (clinicaltrials.gov) - May 18, 2014
P3, N=30, Completed, Sponsor: Octapharma
Trial primary completion date: Dec 2013 --> Feb 2014 Trial completion date: Dec 2013 --> Apr 2014
- | Wilate (human factor VIII/von Willebrand factor) / Octapharma
Enrollment change, Surgery: WONDERS: Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (clinicaltrials.gov) - May 18, 2014
P3, N=30, Completed, Sponsor: Octapharma
Trial completion date: Dec 2013 --> Apr 2014 N=41 --> 30
- || Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial completion, Surgery: WONDERS: Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (clinicaltrials.gov) - May 18, 2014
P3, N=30, Completed, Sponsor: Octapharma
N=41 --> 30 Recruiting --> Completed
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial primary completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - May 18, 2014
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed Trial primary completion date: Sep 2015 --> Oct 2015
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - May 18, 2014
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Sep 2015 --> Oct 2015 Trial completion date: Sep 2015 --> Oct 2015
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - May 18, 2014
P2, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2015 --> Oct 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia (clinicaltrials.gov) - May 15, 2014
P=N/A, N=150, Recruiting, Sponsor: The University of Texas Health Science Center, Houston
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- Trial completion date: Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia (clinicaltrials.gov) - May 15, 2014
P=N/A, N=150, Recruiting, Sponsor: The University of Texas Health Science Center, Houston
Trial primary completion date: Jun 2014 --> Jun 2015 Trial completion date: Jun 2014 --> Jun 2016
- Trial primary completion date: Total Marrow Irradiation for Refractory Acute Leukemia (clinicaltrials.gov) - May 14, 2014
P1, N=20, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial completion date: Jun 2014 --> Jun 2016 Trial primary completion date: Sep 2013 --> Sep 2017
- Trial primary completion date, Metastases: T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - May 14, 2014
P1, N=39, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Sep 2013 --> Sep 2017 Trial primary completion date: Jul 2014 --> Nov 2014
- Trial initiation date: Total Marrow Irradiation for Refractory Acute Leukemia (clinicaltrials.gov) - May 14, 2014
P1, N=20, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Jul 2014 --> Nov 2014 Initiation date: Sep 2007 --> Aug 2012
- Mekinist (trametinib) / Novartis, BeiGene
New P2 trial: UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib (clinicaltrials.gov) - May 14, 2014
P2, N=23, Not yet recruiting, Sponsor: University of Arkansas
- New P3 trial: An Investigation of rhTPO With Different Frequencies in the Management of ITP (clinicaltrials.gov) - May 13, 2014
P3, N=30, Recruiting, Sponsor: Shandong University
- | methylprednisolone sodium succinate / Generic mfg.
Clinical: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) - May 12, 2014
P3, N=36, Recruiting, Sponsor: The Hospital for Sick Children
Initiation date: Sep 2007 --> Aug 2012 Trial primary completion date: Jan 2009 --> Dec 2014
- methylprednisolone sodium succinate / Generic mfg.
Clinical: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) - May 12, 2014
P3, N=36, Recruiting, Sponsor: The Hospital for Sick Children
Trial primary completion date: Jan 2009 --> Dec 2014 Trial completion date: Jan 2010 --> Jul 2015
- Mozobil (plerixafor) / Sanofi
Trial primary completion date, HEOR: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation (clinicaltrials.gov) - May 12, 2014
P4, N=250, Recruiting, Sponsor: University of Florida
Trial completion date: Jan 2010 --> Jul 2015 Trial primary completion date: Mar 2014 --> Apr 2015
- Mozobil (plerixafor) / Sanofi
Trial completion date, HEOR: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation (clinicaltrials.gov) - May 12, 2014
P4, N=250, Recruiting, Sponsor: University of Florida
Trial primary completion date: Mar 2014 --> Apr 2015 Trial completion date: Apr 2015 --> Apr 2016
- Mozobil (plerixafor) / Sanofi
Enrollment open, HEOR: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation (clinicaltrials.gov) - May 12, 2014
P4, N=250, Recruiting, Sponsor: University of Florida
Trial completion date: Apr 2015 --> Apr 2016 Active, not recruiting --> Recruiting
- Mozobil (plerixafor) / Sanofi
Enrollment change, HEOR: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation (clinicaltrials.gov) - May 12, 2014
P4, N=57, Active, not recruiting, Sponsor: University of Florida
Active, not recruiting --> Recruiting N=250 --> 57
- Sylvant (siltuximab) / Jazz
Trial primary completion date: Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - May 12, 2014
P1/2, N=14, Completed, Sponsor: M.D. Anderson Cancer Center
N=250 --> 57 Trial primary completion date: May 2019 --> May 2014
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial: A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia ?ITP? (clinicaltrials.gov) - May 12, 2014
P3, N=60, Recruiting, Sponsor: Shandong University
- | Sylvant (siltuximab) / Jazz
Trial completion: Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - May 12, 2014
P1/2, N=14, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2019 --> May 2014 Active, not recruiting --> Completed
- | Sylvant (siltuximab) / Jazz
Enrollment change: Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - May 12, 2014
P1/2, N=11, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=66 --> 11
- Genasense (oblimersen) / Genta, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 12, 2014
P2, N=120, Completed, Sponsor: National Cancer Institute (NCI)
N=66 --> 11 N=48 --> 120
- melphalan / Generic mfg.
Enrollment closed: Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients (clinicaltrials.gov) - May 11, 2014
P2, N=140, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
N=48 --> 120 Recruiting --> Active, not recruiting
- Sutent (sunitinib) / Pfizer
Trial completion date: Sunitinib in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - May 11, 2014
P2, N=13, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Apr 2009 --> Aug 2010
- Kymriah (tisagenlecleucel-T) / Novartis
New P1 trial: CART-19 for Multiple Myeloma (clinicaltrials.gov) - May 8, 2014
P1, N=15, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - May 7, 2014
P2, N=25, Completed, Sponsor: Steven P. Treon, MD, PhD
Trial completion date: Apr 2009 --> Aug 2010 Active, not recruiting --> Completed
- || Empliciti (elotuzumab) / AbbVie, BMS
Trial primary completion date: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 6, 2014
P2, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Jun 2014
- | Empliciti (elotuzumab) / AbbVie, BMS
Trial initiation date, Combination therapy: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - May 6, 2014
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2015 --> Jun 2014 Initiation date: Jun 2012 --> May 2012
- ||| Empliciti (elotuzumab) / AbbVie, BMS
Trial initiation date: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 6, 2014
P2, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jun 2012 --> May 2012 Initiation date: Jan 2012 --> Nov 2011
- Empliciti (elotuzumab) / AbbVie, BMS
Trial initiation date, Combination therapy: Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone (clinicaltrials.gov) - May 6, 2014
P1, N=20, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2012 --> Nov 2011 Initiation date: Feb 2011 --> Jan 2011
- || Empliciti (elotuzumab) / AbbVie, BMS
Trial completion date: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 6, 2014
P2, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Feb 2011 --> Jan 2011 Trial completion date: Apr 2015 --> Jun 2015
- Biostate (factor VIII/von Willebrand factor) / CSL Behring
Trial completion date: Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development (clinicaltrials.gov) - May 6, 2014
P3, N=1, Terminated, Sponsor: CSL Behring
Trial completion date: Apr 2015 --> Jun 2015 Trial completion date: Nov 2015 --> Dec 2013
- Biostate (factor VIII/von Willebrand factor) / CSL Behring
Trial termination: Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development (clinicaltrials.gov) - May 6, 2014
P3, N=1, Terminated, Sponsor: CSL Behring
Trial completion date: Nov 2015 --> Dec 2013 Recruiting --> Terminated
- Biostate (factor VIII/von Willebrand factor) / CSL Behring
Enrollment change: Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development (clinicaltrials.gov) - May 6, 2014
P3, N=1, Terminated, Sponsor: CSL Behring
Recruiting --> Terminated N=20 --> 1
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial primary completion date: Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - May 6, 2014
P2, N=14, Recruiting, Sponsor: New York University School of Medicine
N=20 --> 1 Trial primary completion date: Aug 2014 --> Dec 2014
- Empliciti (elotuzumab) / AbbVie, BMS
Trial primary completion date, Combination therapy: Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone (clinicaltrials.gov) - May 6, 2014
P1, N=20, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2014 --> Dec 2014 Trial primary completion date: Sep 2013 --> Feb 2014
- | Empliciti (elotuzumab) / AbbVie, BMS
Enrollment open, Combination therapy: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - May 6, 2014
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2013 --> Feb 2014 Active, not recruiting --> Recruiting
- Trial primary completion date: Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant (clinicaltrials.gov) - May 5, 2014
P=N/A, N=12, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Recruiting Trial primary completion date: Nov 2014 --> Dec 2014
- Trial completion date: Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant (clinicaltrials.gov) - May 5, 2014
P=N/A, N=12, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Nov 2014 --> Dec 2014 Trial completion date: Nov 2014 --> Dec 2014
- Clinical: Evaluation of the TICCS Capacity to Identify Trauma Patients With Acute Coagulopathy and Massive Bleeding (clinicaltrials.gov) - May 5, 2014
P=N/A, N=82, Completed, Sponsor: Centre Hospitalier Régional de la Citadelle
- Trial primary completion date: Coagulation Changes in Trauma Patients (clinicaltrials.gov) - May 4, 2014
P=N/A, N=40, Completed, Sponsor: University of Miami
Trial completion date: Nov 2014 --> Dec 2014 Trial primary completion date: Jan 2014 --> Jun 2012
- Trial completion date: Coagulation Changes in Trauma Patients (clinicaltrials.gov) - May 4, 2014
P=N/A, N=40, Completed, Sponsor: University of Miami
Trial primary completion date: Jan 2014 --> Jun 2012 Trial completion date: Jun 2014 --> Jun 2012
- bortezomib / Generic mfg.
Trial primary completion date: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients (clinicaltrials.gov) - May 4, 2014
P2, N=10, Recruiting, Sponsor: University of Utah
Trial completion date: Jun 2014 --> Jun 2012 Trial primary completion date: Dec 2013 --> Jul 2015
- bortezomib / Generic mfg.
Trial completion date: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients (clinicaltrials.gov) - May 4, 2014
P2, N=10, Recruiting, Sponsor: University of Utah
Trial primary completion date: Dec 2013 --> Jul 2015 Trial completion date: Dec 2013 --> Jul 2015